Written and maintained by CASRAI Editorial Board
Last updated
Short answer
CRISPRa (CRISPR activation) turns a target gene up without changing its DNA sequence. It uses a nuclease-dead Cas9 (dCas9) that is guided to a gene’s promoter by a guide RNA and carries a transcriptional activator, such as VP64, to switch the gene on. The main designs differ in how many activator copies reach the locus and in how many constructs a lab must deliver: dCas9-VP64, dCas9-VPR, SAM and SunTag.
What CRISPRa is, and what it is not
Standard CRISPR-Cas9 cuts DNA. CRISPRa does not. In the Nature Reviews Neuroscience review by Yim, Teague and Nestler (2020), dCas9 is described as a nuclease-dead Cas9 that does not cut DNA but is guided to a locus to recruit effector domains: an activator such as VP64 to increase transcription, or a repressor such as KRAB to decrease it. The repressive version is usually called CRISPRi (CRISPR interference).
That makes CRISPRa a gain-of-function tool at the level of expression: the cell’s own copy of the gene is made more active, rather than a cDNA being added or the sequence being edited. It sits beside knockout and knockdown approaches such as shRNA knockdown, which reduce a gene’s output rather than raise it. The idea of using dCas9 for gene regulation traces to Qi and colleagues (2013), and CRISPRa itself was first published by Bikard et al. and Perez-Pinera et al. in 2013, as cited in the Addgene overview below.
How the activator systems are built
Every CRISPRa design has the same two jobs: bring dCas9 to the promoter with a guide RNA, and bring activation domains with it. The designs differ in how the activation domains are attached. Addgene’s comparison of CRISPR activators describes the main families.
dCas9-VP64
The first-generation activator fuses VP64 directly to dCas9. Activation is modest (some genes rise around 2-fold), so it suits experiments that only need a modest increase.
dCas9-VPR
VPR fuses a tripartite VP64-p65-Rta activator to dCas9. Addgene reports it is much stronger than VP64, weaker than SAM and similar to SunTag. Because it is a single fusion protein, it is simpler to deliver than the two-component SAM and SunTag systems.
SAM (Synergistic Activation Mediator)
SAM combines dCas9-VP64 with an engineered guide RNA that carries aptamers. The aptamers bind MS2 proteins, which in turn recruit the HSF1 and p65 activation domains. Addgene states that SAM consistently shows the highest levels of activation for single genes, and that for multiplex activation it is comparable to VPR and SunTag (Chavez et al., 2016).
SunTag
SunTag links dCas9 to a repeating peptide array so that several VP64 copies bind each locus (Tanenbaum et al., 2014). Yim et al. note that the scaffold can recruit up to 24 scFv-fused effectors per gene. Addgene lists its drawbacks as reliance on antibody chains, large size and inconsistent expression.
Newer combinations
SPH combines the SunTag epitope array with the p65-HSF1 domains from SAM, and was reported to give 2-3 times the activation of SAM, SunTag and VPR (Zhou et al., 2018); Yim et al. call it the most potent activator they describe. dCas9 fused to the histone acetyltransferase CBP gave higher activation than SAM at some loci in Drosophila cells (Sajwan and Mannervik, 2019). Addgene notes that these newer methods have not yet been rigorously compared.
Comparing the main systems
Strength is relative, as reported by Addgene.
| System | How the activator reaches the locus | Reported strength | Source |
|---|---|---|---|
| dCas9-VP64 | VP64 fused directly to dCas9 | Modest; some genes about 2-fold | Addgene |
| dCas9-VPR | Single fusion of VP64-p65-Rta | Much stronger than VP64; weaker than SAM; similar to SunTag | Addgene |
| SAM | dCas9-VP64 plus aptamer-bearing guide RNA recruiting MS2-linked HSF1 and p65 | Highest for single genes; comparable to VPR and SunTag in multiplex | Addgene |
| SunTag | Peptide array on dCas9 recruiting multiple VP64 copies | Above first generation; lower than SAM; similar to VPR | Addgene |
| SPH | SunTag array with SAM’s p65-HSF1 domains | Reported 2-3 times SAM, SunTag and VPR in one study | Addgene; Yim et al. |
One practical difference concerns delivery. A Bite Size Bio how-to guide notes that Cas9-VPR, being one large fusion, needs one lentivirus (though its size may lower titers), while SAM and SunTag typically need two. This is a practical observation from a how-to guide, not a standard. For vector production details see the guide to the lentiviral transduction protocol.
Controls and caveats checklist
Yim et al. raise several cautions that apply to any CRISPRa experiment. Use them as a checklist when planning or reviewing one:
- Empty-dCas9 control. dCas9 binding alone is thought to attenuate transcription through steric hindrance of RNA polymerase II, so a dCas9 control without the activator matters.
- Several guides on one promoter. Targeting guide RNAs to several positions along the same promoter can activate transcription synergistically.
- Off-target binding. Off-target dCas9 binding is a recognised concern, even though dCas9 does not cut.
- Supraphysiological induction. CRISPRa and CRISPRi often produce changes larger than physiological ones, and very potent activators may over-induce the target.
- Delivery size. AAV packaging capacity limits what can be delivered; smaller orthologues such as dSaCas9 are one workaround.
Bite Size Bio also reports that effective guide RNAs usually bind the promoter roughly 50 to 400 bp upstream of the transcription start site, with guides outside that window less effective on average. Bite Size Bio presents this as an average trend, not a hard cutoff.
Where it matters for labs and biosafety review
Because CRISPRa leaves the sequence unedited, it is often grouped mentally with editing, but oversight still depends on the delivery system and the biological material involved. Lentiviral and AAV vectors, the cell lines and any in vivo work usually pass through local biosafety review; see what an institutional biosafety committee is for how that review works. For the wider debate around CRISPR technologies, see CRISPR ethics, and for the field background see what genomics is.
When a methods section describes a CRISPRa screen or line, the details a reader needs are the activator system (for example VPR or SAM), the number of constructs delivered, the guide positions relative to the promoter, and the control used for dCas9 alone.
Common misunderstandings
- CRISPRa is not gene editing. It does not cut or change the DNA sequence; dCas9 only recruits an activator to the locus.
- Stronger is not always better. Potent activators can push expression beyond physiological levels, so the strongest system is not automatically the best fit for an experiment.
- dCas9 alone is not inert. Binding is thought to affect transcription by itself, which is why a dCas9-only control is used.
- The ranking is not final. Comparisons such as SAM versus VPR come from specific studies and cell types, and newer systems are not yet rigorously compared.
FAQ
What does CRISPRa stand for?
CRISPRa stands for CRISPR activation: using a catalytically dead Cas9 fused to or paired with transcriptional activators to increase expression of a chosen gene.
What is the difference between CRISPRa and CRISPRi?
Both use dCas9 guided to a locus. CRISPRa recruits an activator such as VP64 to raise transcription; CRISPRi recruits a repressor such as KRAB to lower it.
Does CRISPRa change DNA?
No. dCas9 does not cut DNA, so the sequence of the target gene is unchanged; the effect comes from the recruited activator domains.
Which CRISPRa system is strongest?
According to Addgene, SAM consistently shows the highest activation for single genes, while SPH was reported in one study to exceed SAM, SunTag and VPR by 2-3 times. Newer methods have not yet been rigorously compared.
Sources
- Addgene blog, CRISPR activators: dCas9-VP64, SAM, SunTag, VPR (checked 2026-10-29).
- Yim YY, Teague CD, Nestler EJ. In vivo locus-specific editing of the neuroepigenome. Nat Rev Neurosci 2020;21(9):471-484. PMC7439525 (checked 2026-10-29).
- Bite Size Bio, CRISPR-based activation (CRISPRa) of genes: a how-to guide (secondary source, checked 2026-10-29).
